| Literature DB >> 35572995 |
Fanfan Xing1, Simon K F Lo1, Susanna K P Lau2, Patrick C Y Woo2.
Abstract
Targeted therapies are widely used for treatment of autoimmune diseases as well as solid organ and hematological malignancies. Various opportunistic infections have been described in patients on targeted therapies. Although case reports or a few case series of listeriosis have been reported to be associated with targeted therapy, most of the cases were related to anti-tumor necrosis factor-α monoclonal antibody. In this study, we describe the epidemiological and clinical profiles of listeriosis in a tertiary hospital in Shenzhen, a Southern Chinese metropolitan city in China. During the 9-year-and-6-month study period, a total of five cases of listeriosis were recorded and all of them had Listeria monocytogenes bacteremia. All five patients had predisposing factors, including corticosteroid (n = 3), targeted therapy (n = 2), pregnancy (n = 2) and anti-interferon gamma autoantibody (n = 1). The two patients who had targeted therapy during their course of cancer treatment received inhibitors of the epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) pathway. The first one was a 52-year-old woman with metastatic adenocarcinoma of the lung. She was given gefitinib (EGFR tyrosine kinase inhibitor), osimertinib (third-generation EGFR tyrosine kinase inhibitor) and afatinib (tyrosine kinase inhibitor that can bind to EGFR, HER2 and HER4). The second one was a 40-year-old woman with carcinoma of the breast with brain metastasis. She was given trastuzumab (anti-HER2 monoclonal antibody) and lapatinib (dual tyrosine kinase inhibitor of the EGFR/HER2 pathway). These two patients represent the second and third reports of listeria infections associated with EGFR/HER2 pathway inhibitors in the literature. Targeted therapy is an important predisposing factor for listeriosis. Listeria infection is an important differential diagnosis in patients on targeted therapy who present with sepsis and/or central nervous system infection, and the use of antibiotic regimens that cover listeria is crucial for empirical treatment. Avoidance of high-risk food items in these patients is important for the prevention of listeriosis.Entities:
Keywords: EGFR; HER2; Listeria monocytogenes; opportunistic infection; targeted therapy
Year: 2022 PMID: 35572995 PMCID: PMC9100811 DOI: 10.3389/fmed.2022.888038
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Patients with listeriosis in the present cohort.
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
| 1 | F/52 | Adenocarcinoma of lung with metastasis | Pemetrexed, cisplantin, dexamethasone, gefitinib, osimertinib, afatinib, radiotherapy | None | Blood | None | Succumbed |
| 2 | F/40 | Breast carcinoma with metastasis | Paclitaxel, dexamethasone, trastuzumab, lapatinib | None | Blood | Ampicillin + gentamicin | Recovered |
| 3 | F/27 | Systemic lupus erythematosus, autoimmune hepatitis, pregnancy | Prednisone, hydroxychloroquine | Leftover meat and vegetable stored in refrigerator | Blood | Ampicillin | Recovered, abortion |
| 4 | F/40 | Sjögren's syndrome, pregnancy | Prednisone, hydroxychloroquine | Bird's nest stored in refrigerator | Blood, placenta | Ampicillin | Recovered, abortion |
| 5 (40) | M/59 | Anti-interferon gamma autoantibody | None | None | Blood, CSF | Ampicillin | Recovered |
CSF, cerebral spinal fluid.
Figure 1(A) Distribution of underlying diseases in patients on targeted therapy with listeriosis. (B) Distribution of the type of targeted therapy in these patients. (C) Distribution of these patients with listeriosis in different countries or regions.
Figure 2Types of listeria infection in patients on targeted therapy.